Prexasertib Shrinks Ovarian Cancer Tumors in a Third of Phase 2 Trial Participants
News
The DNA repair inhibitor prexasertib shrank the tumors of a third of the ovarian cancer patients treated with it in a Phase 2 clinical trial, preliminary results show. Its developer, Eli ... Read more